We are happy to announce that Quantify’s Trolle Jacobson and Thomas Fast has presented Q-PARK, one of our research platforms at ISPOR. With Q-PARK, it is possible to analyze switches and HCRU for patients with Parkinson´s disease. See the full […]
A new systematic literature review on patient quality of life in Alzheimer’s disease is now published. The study was co-authored by Anders Gustavsson and is part of the Innovative Medicines Initiative project […]
Quantify’s Ingrid, Mathias and Kirk are co-authors on an population-based Swedish RWE study of incidence of psoriaticarthritis in adults with skin psoriasis published in Acta D-V, and presented at AAD2020. The results showed that if 10,000 patients with skin psoriasis […]
Anders Gustavsson is co-author of a recently published Alzheimer study presenting a cross-walk between the generic health utility measure EQ5D and the disease specific health-related quality of life measure QoL-AD.
A free full text version is available here.
Anders Gustavsson, Partner at Quantify, is a panelist at a HTAi symposium on the value of delaying progression in early Alzheimer’s disease on October 13, sponsored by Biogen.
See full program on https://htai.eventsair.com/htaibeijing2020/#program.
Coordinated by EMA, the European Network of Centers for Pharmacoepidemiology & Pharmacovigilance (ENCePP) is an initiative that brings together expertise and resources in pharmacoepidemiology and pharmacovigilance across Europe with the aim to facilitate the conduct of high quality, multi-center, independent […]
Do you have a genuine interest in improving health care and want to work in an exciting international environment at a growing HEOR consultancy? Are you a team player with an analytical mindset and excellent communication skills? We are looking […]
Paper on Economic consequences of migraine in Sweden, and the cost-effectiveness of Botox for chronic migraine in Sweden and Norway’, co-authored by Quantify, has been published in JHP
The paper ‘Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway’ co-authored by Quantify’s Fredrik Borgström, Amanda Hansson-Hedblom and Isabelle Axelsson, has been published in the Journal of […]